AG真人官方

STOCK TITAN

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Indivior (Nasdaq: INDV) has completed the cancellation of its secondary listing on the London Stock Exchange effective July 25, 2025 at 8:00 a.m. UK time. The delisting includes the removal from both the UK Financial Conduct Authority's Official List and the London Stock Exchange's main market for listed securities.

The company will maintain its primary listing on the Nasdaq Stock Market. To assist shareholders with this transition, Indivior has made available an FAQ document on their investor relations website.

Indivior (Nasdaq: INDV) ha completato la cancellazione della sua quotazione secondaria alla Borsa di Londra, con effetto dal 25 luglio 2025 alle ore 8:00 (ora del Regno Unito). La rimozione riguarda sia l'elenco ufficiale della Financial Conduct Authority del Regno Unito sia il mercato principale della Borsa di Londra per i titoli quotati.

La societ脿 manterr脿 la sua quotazione primaria sul Nasdaq Stock Market. Per agevolare gli azionisti in questa transizione, Indivior ha reso disponibile un documento FAQ sul sito web delle relazioni con gli investitori.

Indivior (Nasdaq: INDV) ha completado la cancelaci贸n de su cotizaci贸n secundaria en la Bolsa de Londres, con efecto a partir del 25 de julio de 2025 a las 8:00 a.m., hora del Reino Unido. La exclusi贸n incluye la eliminaci贸n tanto de la Lista Oficial de la Autoridad de Conducta Financiera del Reino Unido como del mercado principal de la Bolsa de Londres para valores cotizados.

La compa帽铆a mantendr谩 su cotizaci贸n primaria en el Nasdaq Stock Market. Para ayudar a los accionistas con esta transici贸n, Indivior ha puesto a disposici贸n un documento de preguntas frecuentes en su sitio web de relaciones con inversores.

Indivior (雮橃姢雼�: INDV)電� 2025雲� 7鞗� 25鞚� 鞓れ爠 8鞁�(鞓侁淡 鞁滉皠)毳� 旮办爯鞙茧 霟半崢 歃濌秾瓯半灅靻岇棎靹滌潣 2彀� 靸侅灔鞚� 瓿奠嫕鞝侅溂搿� 旆唽頃橃榾鞀惦媹雼�. 鞚措矆 靸侅灔 韽愳電� 鞓侁淡 旮堨湹臧愲弲觳潣 瓿奠嫕 氇呺秬鞕 霟半崢 歃濌秾瓯半灅靻� 欤检殧 鞁滌灔鞐愳劀鞚� 靸侅灔 氇憪鞐愳劀鞚� 鞝滉卑毳� 韽暔頃╇媹雼�.

须岇偓电� 雮橃姢雼� 歃濌秾瓯半灅靻岇棎靹滌潣 1彀� 靸侅灔鞚� 鞙犾頃� 鞓堨爼鞛呺媹雼�. 欤检<霌れ澊 鞚� 鞝勴櫂鞚� 鞗愴櫆頌� 頃� 靾� 鞛堧弰搿� Indivior電� 韴瀽鞛� 甏瓿� 鞗轨偓鞚错姼鞐� FAQ 氍胳劀毳� 鞝滉车頃橁碃 鞛堨姷雼堧嫟.

Indivior (Nasdaq : INDV) a finalis茅 la radiation de sa cotation secondaire 脿 la Bourse de Londres, effective 脿 partir du 25 juillet 2025 脿 8h00, heure du Royaume-Uni. Cette radiation comprend la suppression de la liste officielle de la Financial Conduct Authority du Royaume-Uni ainsi que du march茅 principal de la Bourse de Londres pour les titres cot茅s.

La soci茅t茅 conservera sa cotation principale sur le Nasdaq Stock Market. Pour accompagner les actionnaires dans cette transition, Indivior a mis 脿 disposition un document FAQ sur son site internet d茅di茅 aux relations investisseurs.

Indivior (Nasdaq: INDV) hat die Streichung seiner Sekund盲rnotierung an der Londoner B枚rse zum 25. Juli 2025 um 8:00 Uhr britischer Zeit abgeschlossen. Die Delistung umfasst die Entfernung sowohl aus der offiziellen Liste der britischen Finanzaufsichtsbeh枚rde als auch vom Hauptmarkt der Londoner B枚rse f眉r gelistete Wertpapiere.

Das Unternehmen beh盲lt seine Prim盲rnotierung an der Nasdaq-B枚rse bei. Um den Aktion盲ren den 脺bergang zu erleichtern, hat Indivior ein FAQ-Dokument auf seiner Investor-Relations-Website bereitgestellt.

Positive
  • None.
Negative
  • Reduced access for UK investors
  • Potential decrease in trading liquidity from single-market listing

SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Authority; and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's 听main market for listed securities, have now been cancelled with effect from 08:00 a.m. UK time today, July 25, 2025 (the "London Delisting"). Indivior continues to maintain its primary listing of Ordinary Shares on the Nasdaq Stock Market.

Indivior has prepared an FAQ document for shareholders in connection with the London Delisting, which is available at .听

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease.听

Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting 听

Cision View original content to download multimedia:

SOURCE Indivior PLC

FAQ

When did Indivior (INDV) delist from the London Stock Exchange?

Indivior delisted from the London Stock Exchange on July 25, 2025 at 8:00 a.m. UK time.

Where are Indivior shares now traded after the London delisting?

Indivior shares continue to maintain their primary listing on the Nasdaq Stock Market under the symbol INDV.

How can shareholders find information about Indivior's London Stock Exchange delisting?

Shareholders can access an FAQ document about the delisting on Indivior's website at www.indivior.com/en/investors/shareholder-information.

Why did Indivior delist from the London Stock Exchange?

While not explicitly stated in the press release, the delisting appears to be part of a strategic move to simplify the company's listing structure by maintaining only its Nasdaq presence.
Indivior

NASDAQ:INDV

INDV Rankings

INDV Latest News

INDV Latest SEC Filings

INDV Stock Data

2.92B
119.93M
3.88%
94.35%
5.71%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
SLOUGH, BERKSHIRE